Efficacy and safety of respiratory syncytial virus vaccination during pregnancy to prevent lower respiratory tract illness in newborns and infants: a systematic review and meta-analysis of randomized controlled trials

作者全名："Ma, Juan; Chen, Long; Tang, ShiFang; Shi, Yuan"

作者地址："[Ma, Juan; Shi, Yuan] Chongqing Med Univ, Dept Neonatol, Childrens Hosp, Chongqing, Peoples R China; [Ma, Juan; Shi, Yuan] China Int Sci & Technol, Cooperat Base Child Dev & Crit Disorders, Chongqing, Peoples R China; [Ma, Juan; Shi, Yuan] Chongqing Key Lab Child Rare Dis Infect & Immun, Chongqing, Peoples R China; [Ma, Juan; Tang, ShiFang] SongShan Gen Hosp, Dept Neonatol, Chongqing, Peoples R China; [Chen, Long] Chongqing Med Univ, Chongqing Hlth Ctr Women & Children, Dept Neonatol, Women & Childrens Hosp, Chongqing, Peoples R China"

通信作者："Shi, Y (通讯作者)，Chongqing Med Univ, Dept Neonatol, Childrens Hosp, Chongqing, Peoples R China.; Shi, Y (通讯作者)，China Int Sci & Technol, Cooperat Base Child Dev & Crit Disorders, Chongqing, Peoples R China.; Shi, Y (通讯作者)，Chongqing Key Lab Child Rare Dis Infect & Immun, Chongqing, Peoples R China."

来源：FRONTIERS IN PEDIATRICS

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001161223200001

JCR分区：Q1

影响因子：2.6

年份：2024

卷号：11

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：respiratory syncytial virus; vaccination; pregnancy; newborns and infants; efficiency; meta-analysis

摘要："To evaluate the effectiveness and safety of respiratory syncytial virus (RSV) vaccination during pregnancy in preventing lower respiratory tract infection (LRTI) in infants and neonates, we conducted a systematic search of randomized controlled trials (RCTs) in five databases (PubMed, Embase and Cochrane Library, Web of Science, Cochrane Center Register of Controlled trial) until 1 May 2023. We performed a meta-analysis of the eligible trials using RevMan5.4.1 software. Our analysis included six articles and five RCTs. The meta-analysis revealed significant differences in the incidences of LRTI [risk ratio (RR): 0.64; 95% confidence interval (CI): 0.43, 0.96; p = 0.03)] and severe LRTI (RR: 0.37; 95% CI: 0.18, 0.79; p = 0.01) between the vaccine group and the placebo group for newborns and infants. These differences were observed at 90, 120, and 150 days after birth (p = 0.003, p = 0.05, p = 0.02, p = 0.03, p = 0.009, p = 0.05). At 180 days after birth, there was a significant difference observed in the incidence of LRTI between the two groups (RR: 0.43; 95% CI: 0.21, 0.90; p = 0.02). The safety results showed a significant difference in the incidence of common adverse events between the two groups (RR: 1.08; 95% CI: 1.04, 1.12; p < 0.0001). However, there was no significant difference observed in the incidence of serious adverse events (RR: 1.05; 95% CI: 0.97, 1.15; p = 0.23), common and serious adverse events (RR: 1.02; 95% CI: 0.96, 1.10; p = 0.23), or common and serious adverse events among pregnant women and newborns and infants (RR: 0.98; 95% CI: 0.93, 1.04; p = 0.52). In conclusion, maternal RSV vaccination is an effective and safe immunization strategy for preventing LRTI in postpartum infants, with greater efficacy observed within the first 150 days after birth."

基金机构：National Key Research and Development Program of China10.13039/501100001809

基金资助正文：No Statement Available